Achieved $8.2 million in OJEMDA net product revenues in initial 2 months of launch.

Expanded pipeline with DAY301, a potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7.

Entered into exclusive licensing agreement with Ipsen to commercialize tovorafenib outside of the U.S. for approximately $111 million upfront.

Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million.